Member Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}



Kuvan

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155. If you have questions regarding the prior authorization, please contact CVS Caremark at 1-866-814-5506. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Pat Ph Sp Ph	tient's Name: {{MEMFIRST}} {{MEMLAST}} pate: {{TODAY}} tient's ID {{MEMBERID}} Patient's Date of Birth: {{MEMBERDOB}} ysician's Name: {{PHYFIRST}} {{PHYLAST}} ecialty:, NPI#: ysician Office Telephone: {{PHYSICIANPHONE}} Physician Office Fax: {{PHYSICIANFAX}} quest Initiated For: {{DRUGNAME}}
1.	What is the diagnosis? Phenylketonuria Biopterin metabolic defects Autosomal dominant guanine triphosphate cyclohydrolase deficiency (Segawa disease) Autosomal recessive guanine (GTP) cyclohydrolase deficiency 6-pyruvoyl-tetrahydropterin synthase (6-PTS) deficiency Sepiapterin reductase deficiency Dihydropteridine reductase (DHPR) deficiency Pterin-4a-carbinolamine dehydralase deficiency (also called primapterinuria) Other
2.	What is the ICD-10 code?
3.	Was the diagnosis confirmed by an enzyme assay, genetic testing, or phenylalanine level? <i>ACTION REQUIRED: If Yes, attach supporting chart note(s) or test results.</i> □ Yes □ No
4.	Is this request for continuation of therapy with Kuvan? If Yes, skip to diagnosis section. Yes In No
5.	Is Kuvan being requested for a biopterin metabolic defect? If Yes, no further questions \square Yes \square No
6.	What is the patient's baseline (with dietary interventions alone) blood phenylalanine (Phe) level? mg/dL or micromol/L (circle one) □ No baseline blood Phe level
7.	Will Kuvan be initiated in a patient currently receiving Palynziq for phenylketonuria? ☐ Yes ☐ No If No, no further questions
8.	Will Palynziq be discontinued after an appropriate period of overlap? Yes No No further questions
Co	mplete the following section based on the patient's diagnosis, if applicable.
<u>Sec</u> 9.	which of the following has the patient demonstrated following the therapeutic trial with Kuvan? Question continues on next page. Reduction in blood phenylalanine (Phe) level of greater than or equal to 30% from baseline
	Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155 This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended

Phenylalanine (Phe) levels in an acceptable range (less than 360 micromol/L or 6 mg/dL) Improvement in neuropsychiatric symptoms None of the above 10. Will Kuvan be used concomitantly with Palynziq for phenylketonuria? Yes No Section B: Biopterin Metabolic Defects 11. Is the patient experiencing benefit from therapy as evidenced by disease stability or disease improvement? Yes - disease stability Yes - disease improvement No, neither disease stability nor disease improvement
Section B: Biopterin Metabolic Defects 11. Is the patient experiencing benefit from therapy as evidenced by disease stability or disease improvement? \(\subseteq \text{ Yes} - \text{ disease improvement} \)
11. Is the patient experiencing benefit from therapy as evidenced by disease stability or disease improvement? ☐ Yes - disease stability ☐ Yes - disease improvement
I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.
X

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Kuvan SGM - 7/2021.